肝脏影像报告和数据系统在肝细胞癌与转移瘤风险患者中的诊断效能
回顾性纳入104例慢性肝病且有肝外恶性肿瘤史的患者,共59个肝细胞癌和45个转移瘤,评估LI-RADS分类的诊断效能。LR-5诊断肝细胞癌的敏感度69%、特异度98%、准确率82%;LR-M诊断转移瘤的敏感度89%、特异度88%、准确率88%。LI-RADS在鉴别肝细胞癌与转移瘤方面具有高特异度(98%)。
要点
- LR-5诊断肝细胞癌特异度高达98%,但敏感度仅69%。
- LR-M诊断转移瘤敏感度89%、特异度88%、准确率88%。
- 癌胚抗原或糖类抗原19-9升高及肿瘤多发更常见于转移瘤。
核心结论
- LI-RADS在同时有慢性肝病和肝外恶性肿瘤史的患者中,鉴别肝细胞癌与转移瘤具有高特异度(98%)。
研究设计与样本
- 回顾性研究纳入2008年至2017年间经病理证实的104例慢性肝病(肝硬化或慢性乙型肝炎)且有肝外恶性肿瘤史的患者,共59个肝细胞癌和45个转移瘤。
关键影像表现/征象
- 两名放射科医师在不知最终诊断的情况下独立审阅95例患者的MRI和9例患者的CT图像,采用共识数据计算LI-RADS分类的诊断效能。
诊断标准与关键数值
- LR-5诊断肝细胞癌的敏感度69%(95%CI 56-81)、特异度98%(95%CI 88-99)、准确率82%(95%CI 73-89)。
- LR-M诊断转移瘤的敏感度89%(95%CI 76-96)、特异度88%(95%CI 77-95)、准确率88%(95%CI 81-94)。
临床应用与阅片要点
- 在同时有慢性肝病和肝外恶性肿瘤史的患者中,LR-5分类对肝细胞癌具有高特异度,可支持肝细胞癌诊断。
- 血清癌胚抗原升高(P=0.01)、糖类抗原19-9升高(P=0.02)及肿瘤多发(P=0.004)在转移瘤中较肝细胞癌更常见。
- 被判为LR-4或LR-5的转移瘤中,4个里有3个小于2 cm。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: The purpose of this study was to evaluate the diagnostic performance of the Liver Imaging Reporting and Data System (LI-RADS) in patients with both chronic liver disease and a history of extrahepatic malignancy.
MATERIALS AND METHODS: This retrospective study included 59 hepatocellular carcinomas (HCCs) and 45 metastases pathologically confirmed between 2008 and 2017 in 104 patients with chronic liver disease (cirrhosis or chronic hepatitis B) and a history of extrahepatic malignancy. Two radiologists blinded to the final diagnosis independently reviewed MRI (95 patients) or CT (9 patients) images, and their consensus data were used to calculate the diagnostic performance of LI-RADS categories. Serum tumor markers, tumor multiplicity, and suspected metastatic lymph nodes were also evaluated.
RESULTS: The sensitivity, specificity, and accuracy of LR-5 for diagnosing HCC were 69% (95% confidence intervals [CI] 56-81), 98% (95% CI 88-99), and 82% (95% CI 73-89), respectively, and those of LR-M for diagnosing metastasis were 89% (95% CI 76-96), 88% (95% CI 77-95), and 88% (95% CI 81-94), respectively. Elevation of serum carcinoembryonic antigen (P = 0.01) or carbohydrate antigen 19-9 levels (P = 0.02) and tumor multiplicity (P = 0.004) were more frequently observed in metastasis than in HCC. Three of four metastases categorized as LR-4 or LR-5 were smaller than 2 cm.
CONCLUSIONS: The LI-RADS provides high specificity (98%) for differentiating HCC from metastases in patients with both chronic liver disease and a history of extrahepatic malignancy.
引用
- Cho MJ, An C, Aljoqiman KS, et al. Diagnostic performance of Liver Imaging Reporting and Data System in patients at risk of both hepatocellular carcinoma and metastasis. Abdom Radiol (NY). 2020. PMID: 32440900. doi:10.1007/s00261-020-02581-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。